MedPath

Eszopiclone

Generic Name
Eszopiclone
Brand Names
Lunesta
Drug Type
Small Molecule
Chemical Formula
C17H17ClN6O3
CAS Number
138729-47-2
Unique Ingredient Identifier
UZX80K71OE
Background

Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.

One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.

Indication

Eszopiclone is indicated for the treatment of insomnia.

Associated Conditions
Insomnia

Safety and Efficacy of Chronic Hypnotic Use 2

Phase 4
Completed
Conditions
Chronic Insomnia
Interventions
First Posted Date
2015-05-28
Last Posted Date
2024-03-29
Lead Sponsor
Henry Ford Health System
Target Recruit Count
41
Registration Number
NCT02456532
Locations
🇺🇸

HFHS Sleep Disorders Ctr, Detroit, Michigan, United States

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

Completed
Conditions
Insomnia
Interventions
First Posted Date
2015-05-27
Last Posted Date
2018-09-07
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
438
Registration Number
NCT02455271

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

Completed
Conditions
Insomnia
Interventions
First Posted Date
2015-05-25
Last Posted Date
2018-09-07
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
4876
Registration Number
NCT02452684

Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-12-23
Last Posted Date
2014-12-23
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
46
Registration Number
NCT02322658
Locations
🇮🇳

BA Research India Limited, Ahmedabad, Gujarat, India

Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-12-23
Last Posted Date
2014-12-23
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
46
Registration Number
NCT02322645
Locations
🇮🇳

BA Research India Limited, Ahmedabad, Gujarat, India

Auricular Acupuncture for Primary Insomnia

Not Applicable
Completed
Conditions
Primary Insomnia
Interventions
Other: auricular acupuncture(AA)
Other: placebo AA
First Posted Date
2014-03-14
Last Posted Date
2020-02-17
Lead Sponsor
Chengdu University of Traditional Chinese Medicine
Target Recruit Count
288
Registration Number
NCT02087488
Locations
🇨🇳

Chengdu university of Traditonal Chinese Medcine, Chengdu, Sichuan, China

Sleep Effectiveness and Insulin and Glucose Homeostasis

Phase 1
Terminated
Conditions
Glucose Intolerance
Prediabetic
Diabetes
Prediabetes
Interventions
First Posted Date
2013-06-27
Last Posted Date
2019-12-19
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
20
Registration Number
NCT01887691
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

Phase 3
Completed
Conditions
Primary Insomnia
Interventions
First Posted Date
2012-10-19
Last Posted Date
2012-10-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
791
Registration Number
NCT01710631

Effects of Eszopiclone on Sleep and Memory in Schizophrenia

Not Applicable
Completed
Conditions
Schizophrenia
Interventions
Drug: placebo
First Posted Date
2012-07-17
Last Posted Date
2017-06-14
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
59
Registration Number
NCT01641900
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Eszopiclone for the Treatment of Posttraumatic Stress Disorder

Phase 4
Completed
Conditions
Posttraumatic Stress Disorders
Interventions
Drug: Placebo
First Posted Date
2012-05-24
Last Posted Date
2022-12-23
Lead Sponsor
Rush University Medical Center
Target Recruit Count
81
Registration Number
NCT01605253
Locations
🇺🇸

Center for Anxiety and Traumatic Stress Disorders at Rush, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath